
May 30 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES MK-1084, AN INVESTIGATIONAL KRAS G12C INHIBITOR, SHOWS ANTITUMOR ACTIVITY IN PHASE 1 TRIAL OF PATIENTS WITH ADVANCED COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER WHOSE TUMORS HARBOR KRAS G12C MUTATIONS
MERCK & CO INC - MK-1084 TO BE INVESTIGATED IN PHASE 3 KANDLELIT-012 AND KANDLELIT-004 STUDIES
MERCK & CO INC - MK-1084 SHOWS MANAGEABLE SAFETY PROFILE AND ANTITUMOR ACTIVITY